Our Clinical-Stage Programs for more information. While we are advancing plans for an additional confirmatory Phase 3 clinical trial for roluperidone for the treatment of negative symptoms in schizophrenia, which we refer to as the C19 trial, in consultation with the FDA and expect to fund such trial and our resubmission of the NDA in part with net proceeds from our October 2025 private placement, there can be no assurances that we will successfully resubmit the NDA and obtain approval for rolup...
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2025-12-31 | 0001193125-26-101117 | EDGAR | 82K words |
| 2025-02-25 | 2024-12-31 | 0000950170-25-026055 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018392 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0000950170-23-006577 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001564590-22-007853 | EDGAR | — |
| 2021-03-08 | 2020-12-31 | 0001564590-21-011340 | EDGAR | — |
| 2020-03-09 | 2019-12-31 | 0001564590-20-009243 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001564590-19-007246 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001564590-18-005224 | EDGAR | — |
| 2017-03-13 | 2016-12-31 | 0001564590-17-004048 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-07 | 2026-06-30 | 0001193125-26-339171 | EDGAR | — |
| 2025-11-05 | 2025-09-30 | 0001193125-25-265685 | EDGAR | 20K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108840 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-069780 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0000950170-24-121063 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091195 | EDGAR | — |
| 2024-05-01 | 2024-03-31 | 0000950170-24-050883 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-059747 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0000950170-23-036159 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021947 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023496 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015754 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-07 | 0001193125-26-339147 | EDGAR | — |
| 2026-04-06 | 0001193125-26-143986 | EDGAR | 1K words |
| 2026-04-02 | 0001193125-26-140148 | EDGAR | — |
| 2026-03-11 | 0001193125-26-101074 | EDGAR | — |
| 2026-02-03 | 0001193125-26-034538 | EDGAR | — |
| 2025-12-22 | 0001193125-25-328715 | EDGAR | — |
| 2025-11-19 | 0001193125-25-287048 | EDGAR | — |
| 2025-10-22 | 0001193125-25-245552 | EDGAR | — |
| 2025-03-19 | 0001193125-25-057901 | EDGAR | — |
| 2025-01-13 | 0001193125-25-005042 | EDGAR | — |
206 total filings indexed. 174 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001598646 |
| Ticker | NERV |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | MA |
| Website | https://www.minervaneurosciences.com |
| Listed | 2014-07-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NERV (~200 tokens, structured JSON with cryptographic provenance)